News See the latest press releases about Pentixapharm. Phillip Eckert 10/27/22 Phillip Eckert 10/27/22 First CNS Lymphoma Patient Imaged with PentixaFor in Phase II Trial Read More Phillip Eckert 4/8/22 Phillip Eckert 4/8/22 Radboud University Medical Center Netherlands to Image First Patient with PENTIXAFOR Read More Phillip Eckert 9/17/21 Phillip Eckert 9/17/21 Nantes University Hospital Doses First Patients with Eckert & Ziegler's Novel Ga-68 Imaging Agent PENTIXAFOR Read More Phillip Eckert 4/19/21 Phillip Eckert 4/19/21 Eckert & Ziegler Strahlen- und Medizintechnik AG Acquires Direct Majority Stake in Drug Developer PENTIXAPHARM Read More Phillip Eckert 2/10/21 Phillip Eckert 2/10/21 PENTIXAPHARM receives confirmation from EMA that its Lead Candidate PENTIXAFOR is ready for Phase III Study Read More Phillip Eckert 2/6/20 Phillip Eckert 2/6/20 PENTIXAPHARM Secures € 15 Million Series A Financing to Develop CXCR4-Targeted Theranostics Read More Phillip Eckert 5/15/19 Phillip Eckert 5/15/19 Scintomics and 1717 Life Science Ventures team up in the joint venture PENTIXAPHARM to develop CXCR4-targeted theranostics Read More Newer Posts
Phillip Eckert 10/27/22 Phillip Eckert 10/27/22 First CNS Lymphoma Patient Imaged with PentixaFor in Phase II Trial Read More
Phillip Eckert 4/8/22 Phillip Eckert 4/8/22 Radboud University Medical Center Netherlands to Image First Patient with PENTIXAFOR Read More
Phillip Eckert 9/17/21 Phillip Eckert 9/17/21 Nantes University Hospital Doses First Patients with Eckert & Ziegler's Novel Ga-68 Imaging Agent PENTIXAFOR Read More
Phillip Eckert 4/19/21 Phillip Eckert 4/19/21 Eckert & Ziegler Strahlen- und Medizintechnik AG Acquires Direct Majority Stake in Drug Developer PENTIXAPHARM Read More
Phillip Eckert 2/10/21 Phillip Eckert 2/10/21 PENTIXAPHARM receives confirmation from EMA that its Lead Candidate PENTIXAFOR is ready for Phase III Study Read More
Phillip Eckert 2/6/20 Phillip Eckert 2/6/20 PENTIXAPHARM Secures € 15 Million Series A Financing to Develop CXCR4-Targeted Theranostics Read More
Phillip Eckert 5/15/19 Phillip Eckert 5/15/19 Scintomics and 1717 Life Science Ventures team up in the joint venture PENTIXAPHARM to develop CXCR4-targeted theranostics Read More
